Rao Chinthalapally V, Sanghera Saira, Zhang Yuting, Biddick Laura, Reddy Arun, Lightfoot Stan, Janakiram Naveena B, Mohammed Altaf, Dai Wei, Yamada Hiroshi Y
Center for Cancer Prevention and Drug Development, Department of Medicine, Hematology/Oncology Section, University of Oklahoma Health Sciences Center, Oklahoma City, Oklahoma.
College of Arts & Sciences, Baylor University, Waco, Texas.
Cancer Res. 2016 Feb 1;76(3):630-42. doi: 10.1158/0008-5472.CAN-15-0940.
Colon cancer is the second most lethal cancer and is predicted to claim 49,700 lives in the United States this year. Chromosome instability (CIN) is observed in 80% to 90% of colon cancers and is thought to contribute to colon cancer progression and recurrence. To investigate the impact of CIN on colon cancer development, we developed shugoshin-1 (Sgo1) haploinsufficient (-/+) mice, an animal model focusing on mitotic error-induced CIN. In this study, we analyzed signature changes in the colonic transcriptome of Sgo1(-/+) mice to examine the molecular events underlying the altered carcinogenesis profiles in Sgo1(-/+) mice. We performed next-generation sequencing of normal-looking colonic mucosal tissue from mice treated with the carcinogen azoxymethane after 24 weeks. Transcriptome profiling revealed 349 hits with a 2-fold expression difference threshold (217 upregulated genes, 132 downregulated genes, P < 0.05). Pathway analyses indicated that the Sgo1-CIN tissues upregulated pathways known to be activated in colon cancer, including lipid metabolism (z score 4.47), Notch signaling (4.47), insulin signaling (3.81), and PPAR pathways (3.75), and downregulated pathways involved in immune responses including allograft rejection (6.69) and graft-versus-host disease (6.54). Notably, stem cell markers were also misregulated. Collectively, our findings demonstrate that systemic CIN results in transcriptomic changes in metabolism, proliferation, cell fate, and immune responses in the colon, which may foster a microenvironment amenable to cancer development. Therefore, therapeutic approaches focusing on these identified pathways may be valuable for colon cancer prevention and treatment.
结肠癌是第二大致命癌症,预计今年在美国将导致49700人死亡。在80%至90%的结肠癌中观察到染色体不稳定(CIN),并且认为其有助于结肠癌的进展和复发。为了研究CIN对结肠癌发生的影响,我们构建了shugoshin-1(Sgo1)单倍体不足(-/+)小鼠,这是一种关注有丝分裂错误诱导的CIN的动物模型。在本研究中,我们分析了Sgo1(-/+)小鼠结肠转录组的特征变化,以检查Sgo1(-/+)小鼠致癌作用改变的潜在分子事件。我们对用致癌物氧化偶氮甲烷处理24周后的小鼠外观正常的结肠黏膜组织进行了二代测序。转录组分析揭示了349个表达差异达到2倍阈值的基因(217个上调基因,132个下调基因,P<0.05)。通路分析表明,Sgo1-CIN组织上调了已知在结肠癌中被激活的通路,包括脂质代谢(z评分4.47)、Notch信号通路(4.47)、胰岛素信号通路(3.81)和PPAR通路(3.75),并下调了参与免疫反应的通路,包括同种异体移植排斥反应(6.69)和移植物抗宿主病(6.54)。值得注意的是,干细胞标志物也出现了失调。总体而言,我们的研究结果表明,全身性CIN导致结肠在代谢、增殖、细胞命运和免疫反应方面的转录组变化,这可能会促进有利于癌症发展的微环境。因此,针对这些已确定通路的治疗方法可能对结肠癌的预防和治疗具有重要价值。